Natural Killer Cells in Autoimmune Diseases

Function and Markers
  • Dag Sørskaar
  • Øystein Førre


Natural killer cell activity was first recognized around 1970 (McCoy et al., 1973; Takasugi et al., 1973). This activity can be demonstrated without the apparent previous sensitization of the effector cells. It has therefore been termed either spontaneous or natural cell-mediated cytotoxicity (Takasugi et al., 1977), spontaneous lymphocyte-mediated or mononuclear cell cytotoxicity (Pross and Baines, 1977), and now usually natural killer (NK) cell activity. The effector cells responsible for this activity are called natural killer cells (NK cells). They are considered to be distinct from other cells capable of mediating spontaneous cytotoxicity such as cytotoxic T lymphocytes and monocytes (Ritz et al., 1988). In vitro lymphokine-activated killer (LAK) cells are interleukin-2 (IL-2)-stimulated lymphocytes with the ability to lyse NK resistant target cells in vivo (Grimm et al., 1982). However, LAK cells have so far not been shown to represent a distinct effector cell population. They mostly appear to represent IL-2-stimulated NK cells with enhanced cytolytic activity (Ritz et al., 1988; Lotzová and Ades, 1989).


Systemic Lupus Erythematosus Natural Killer Cell Systemic Lupus Erythematosus Patient Natural Killer Cell Activity Juvenile Rheumatoid Arthritis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abo, T., and Balch, C. M., 1981, A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1), J. Immunol 127:1024–1029.PubMedGoogle Scholar
  2. Abom, B., and Pedersen, B. K., 1987, The in vivo effect of triethylphosphine gold (auranofin), sodium aurothiomalate and azathioprine on natural killer cell activity of patients with rheumatoid arthritis, Clin. Exp. Rheumatol 5:47–52.PubMedGoogle Scholar
  3. Anderson, C. L., and Looney, J. R., 1986, Human leukocyte IgG Fc receptors, Immunol. Today 7:264–266.CrossRefGoogle Scholar
  4. Ausiello, C. M., Barbieri, P., Spagnoli, G. C., Ciompi, M. L., and Casciani, C. U., 1986, In vivo effects of chloroquine treatment on spontaneous and interferon-induced natural killer activities in rheumatoid arthritis patients. Clin. Exp. Rheum. 4:255–259.Google Scholar
  5. Bakacs, T., Gergely, P., and Klein, E., 1977, Characterization of cytotoxic human lymphocyte subpopulations: The role of Fcreceptor-carrying cells, Cell Immunol. 32:317–328.CrossRefPubMedGoogle Scholar
  6. Biron, C. A., Byron, K. S., & Sullivan, J. L., 1989, Severe herpesvirus infections in an adolescent without natural killer cells, N. Engl. J. Med. 320:1731–1735.CrossRefPubMedGoogle Scholar
  7. Bonavida, B., and Wright, S. C., 1986, Role of natural killer cytotoxic factors in the mechanism of target-cell killing by natural killer cells, J. Clin. Immunol. 6:1–8.CrossRefPubMedGoogle Scholar
  8. Burmester, G. R., Kalden, J. R., Peter, H. H., Schodel, I., Beck, P., and Wittenberg, A., 1978, Immunological and functional characteristics of peripheral blood and synovial fluid lymphocytes from patients with rheumatoid arthritis. Scand. J. Immunol. 7:405–417.CrossRefPubMedGoogle Scholar
  9. Combe, B., Pope, R. M., Fischbach, M., Darnell, B., Baron, S., and Talal, N., 1985, Interleukin-2 in rheumatoid arthritis: Production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood, Clin. Exp. Immunol. 59:520–528.PubMedGoogle Scholar
  10. Cseuz, R., and Panayi, G. S., 1990, The inhibition of NK cell function by azathioprine during the treatment of patients with rheumatoid arthritis, Br. J. Rheumatol. 29:358–362.CrossRefPubMedGoogle Scholar
  11. Cseuz, R., Barnes, P., and Panayi, G. S., 1990, Natural killer cells in the blood of patients with rheumatoid arthritis treated with azathioprine, Br. J. Rheumatol. 29:284–287.CrossRefGoogle Scholar
  12. Dinarello, C. A., Conti, P., and Mier, J. W., 1986, Effects of human interleukin-1 on natural killer cell activity: Is fever a host defense mechanism for tumor killing? Yak J. Biol. Med. 59:97–106.Google Scholar
  13. Egan, M. L., Mendelsohn, S. L., Abo, T., and Balch, C. M., 1983, Natural killer cells in systemic lupus erythematosus. Abnormal numbers and functional immaturity of HNK-1+ cells, Arthritis Rheum. 26:623–629.CrossRefPubMedGoogle Scholar
  14. Enk, C., and Oxholm, P., 1988, Decreased interleukin-1 responsiveness of blood lymphocytes in patients with primary Sj0gren’s syndrome, Clin. Exp. Rheumatol. 6:67–69.PubMedGoogle Scholar
  15. Enk, C., Oxholm, P., Tvede, N., and Bendtzen, K., 1986, Blood mononuclear cells in patients with primary Sjøgren’s syndrome: Production of interleukins, enumeration of interleukin-2 receptors, and DNA synthesis, Scand. J. Rheumatol. 615:131–138.Google Scholar
  16. Faltynek, C. R., Princier, G. L., and Ortaldo, J. R., 1986, Expression of IFN-alpha and IFN-gamma receptors on normal human small resting T lymphocytes and large granular lymphocytes, J. Immunol. 136:4134–4139.PubMedGoogle Scholar
  17. Førre, Ø., Dobloug, J. H., Heyeraal, H. M., and Thorsby, E., 1983, HLA antigens in juvenile arthritis. Genetic basis for the different subtypes, Arthritis Rheum. 26:35–38.CrossRefPubMedGoogle Scholar
  18. Førre, Ø., Waalen, K., Thoen, J., and Hovig, T., 1985, Macrophages and dendritic cells in rheumatic diseases, in: Immunology of Rheumatic Diseases (S. Gupta and N. Talal, eds.), Plenum Press, New York, pp. 543–562.CrossRefGoogle Scholar
  19. Garcia-Penarrubia, P., Koster, F. T., Kelley, R. O., McDowell, T. D, and Bankhurst, A. D., 1989, Antibacterial activity of human natural killer cells, J. Exp. Med. 169:99–133.CrossRefPubMedGoogle Scholar
  20. Gerli, R., Bertotto, A., Cernetti, C., Agea, E., Crupi, S., Arcangeli, C., Spinozzi, F., Galandrini, R., and Rambotti, P., 1989, Anti-CD3 and anti-CD2-induced T-cell activation in primary Sjøgren’s syndrome, Clin. Exp. Rheum. 7/S-3:129–134.Google Scholar
  21. Gidlund, M., Orn, A., Wigzell, H., Senik, A., and Gresser, I., 1978, Enhanced NK cell activity in mice injected with interferon and interferon inducers, Nature 273:759–761.CrossRefPubMedGoogle Scholar
  22. Golstein, P., 1987, Cytotoxic T-cell melodrama, Nature 327:12.CrossRefPubMedGoogle Scholar
  23. Gonzalez-Amaro, R., Alcocer-Varela, J., and Alarcon-Segovia, D., 1988, Natural killer cell activity in the systemic connective tissue diseases, J. Rheum. 15:1223–1228.PubMedGoogle Scholar
  24. Goto, M., Tanimoto, K., and Horiuchi, Y., 1980, Natural cell mediated cytotoxicity in systemic lupus erythematosus: Suppression by antilymphocyte antibody, Arthiritis Rheum. 23(11):1274–1281.CrossRefGoogle Scholar
  25. Goto, M., Tanimoto, K., Chihara, T., and Horiuchi, Y. I., 1981, Natural cell-mediated cytotoxicity in Sj0gren’s syndrome and rheumatoid arthritis, Arthritis Rheum. 24:1377–1382.CrossRefPubMedGoogle Scholar
  26. Grimm, E. A., Mazumder, A., Zhang, H. Z., and Rosenberg, S. A., 1982, Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes, J. Exp. Med. 155:1823–1841.CrossRefPubMedGoogle Scholar
  27. Hansson, M., Beran, M., Andersson, B., and Kiessling, R., 1982, Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells, J. Immunol. 129:126–132.PubMedGoogle Scholar
  28. Herberman, R. B., Djeu, J. Y., Kay, H. D., Ortaldo, J. R., Riccardi, C., Bonnard, G. D., Holden, H. T., Fagnani, R., Santoni, A. S., and Puccetti, R, 1979, Natural killer cells: Characteristics and regulation of activity, Immunol Rev. 44:43–70.CrossRefPubMedGoogle Scholar
  29. Hercend, T., and Schmidt, R. E., 1988, Characteristics and uses of natural killer cells, Immunol Today 9:291–293.CrossRefPubMedGoogle Scholar
  30. Hercend, T., Reinherz, E. L., Meuer, S., Schlossman, S. F., and Ritz, J., 1983, Phenotypic and functional heterogeneity of human cloned natural killer cell lines, Nature 301:158–160.CrossRefPubMedGoogle Scholar
  31. Hoffman, T., 1980, Natural killer function in systemic lupus erythematosus, Arthritis Rheum. 23:30–35.CrossRefPubMedGoogle Scholar
  32. Katz, D., Zatoun, A., Lee, J. A., Punush, R. S., and Longley, S., 1982, Abnormal killer cell activity in systemic lupus erythematosus: An intrinsic defect in the lytic event, J. Immunol 129:1966–1971.PubMedGoogle Scholar
  33. Knapp, W., Rieber, P., Dörken, B., Schmidt, R. E., Stein, H., and v. d. Borne, A. E. G., Jr., 1987, Towards a better definition of human leucocyte surface molecules, Immunol Today 10:253–258.CrossRefGoogle Scholar
  34. Kremer, J. M., Galivan, J., Streckfuss, A., and Kamen, B., 1986, Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients: Association with hepatic folate deficiency and formation of polyglutamates, Arthritis Rheum. 29:832–835.CrossRefPubMedGoogle Scholar
  35. Lanier, L. L., Le, A. M., Phillips, J. H., Warner, N. L., and Babcock, G. E., 1983, Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens, J. Immunol 131:1789–1796.PubMedGoogle Scholar
  36. Linker-Israeli, M., Bakke, A. C., Kitridou, R. C., Gendler, S., Gillis, S., and Horwitz, D. A., 1983, Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus (SLE), J. Immunol. 130:2651–2655.PubMedGoogle Scholar
  37. Lipsky, P. E., 1984, Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper-orceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes, J. Clin. Invest. 73:53–65.CrossRefPubMedGoogle Scholar
  38. Lotzová, E., and Ades, E. W., 1989, Natural killer cells: Definition, heterogeneity, lytic mechanism, functions and clinical application. Highlights of the Fifth International Workshop on Natural Killer Cells, Hilton Head Island, N.C., Nat. Immun. Cell Growth Regul. 8:1–9.PubMedGoogle Scholar
  39. Lotzová, E., Savary, C. A., and Pollack, S. B., 1983, Prevention of rejection of allogeneic bone marrow transplants by NK 1.1 antiserum, Transplantation 35:490–494.CrossRefPubMedGoogle Scholar
  40. Luder, A. S., Naphtali, V, Porat, E. B., and Lahat, N., 1989, Still’s disease associated with adenovirus infection and defect in adenovirus directed natural killing, Ann. Rheum. Dis. 48:781–786.CrossRefPubMedGoogle Scholar
  41. Malejczyk, J., Kaminiski, M. J., Malejczyk, M., and Majewski, S., 1985, Natural cell-mediated cytotoxic activity against isolated chondrocytes in the mouse, Clin. Exp. Immunol 59:110–116.PubMedGoogle Scholar
  42. Maluish, A. E., Ortaldo, J. R., Conlon, J. C., Sherwin, S. A., Leawitt, R., Strong, D. M., Weirnik, P., Oldham, R. K., and Herberman, R. B., 1983, Depression of natural killer cytotoxicty after in vivo administration of recombinant leukocyte interferon, J. Immunol 131:503–507.PubMedGoogle Scholar
  43. Manthorpe, R., Frost-Larsen, K., Isager, H., and Prause, J. U., 1981, Sj0gren’s syndrome. A review with emphasis on immunological features, Allergy 36:139–153.CrossRefPubMedGoogle Scholar
  44. McCoy, J. L., Herberman, R. B., Rosenberg, E. B., Donnelly, E C., Levine, P. H., and Alford, C., 1973,51Chromium-release assay for cell-mediated cytotoxicity of human leukemia and lymphoid tissue-culture cells, Natl. Cancer Inst. Monogr. 37:59–67.PubMedGoogle Scholar
  45. Miyasaka, N., Sauvezie, B., and Pierce, D., 1981, Decreased autologous mixed lymphocyte reaction in Sj0gren’s syndrome, J. Clin. Invest. 66:928–932.CrossRefGoogle Scholar
  46. Miyasaka, N., Seaman, W., Bakshi, A., Sauvezie, B., Strand, V., Pope, R., and Talal, N., 1983, Natural killing activity in Sjøgren’s syndrome. An analysis of the defective mechanisms, Arthritis Rheum. 26:954–960.CrossRefPubMedGoogle Scholar
  47. Miyiasaka, N., Darnell, B., Baron, T., and Talal, N., 1984a, Interleukin 2 enhances natural killing of normal lymphocytes, Cell. Immunol 84:154–162.CrossRefGoogle Scholar
  48. Miyasaka, N., Nakamura, T., Russell, I. J., and Talal, N., 1984b, Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus, Clin. Immunol Immunopathol. 31:109–117.CrossRefPubMedGoogle Scholar
  49. Morio, T., Nonoyama, S., and Yata, J., 1989, Suppression of in vitro immunoglobulin synthesis by CD16 (Leu lia)+ CD56 (NKH1, Leu 19)+ non-T lineage cells; lack of suppression of cells from immunodeficient patients, Clin. Exp. Immunol 78:159–165.PubMedGoogle Scholar
  50. Neighbour, P. A., Grayzel, A. I., and Miller, A. E., 1982, Endogenous and interferon-augmented natural killer cell activity of human peripheral blood mononuclear cells in vitro. Studies of patients with multiple sclerosis, systemic lupus erythematosus or rheumatoid arthritis, Clin. Exp. Immunol. 49:11–21.PubMedGoogle Scholar
  51. Onsrud, M., and Thorsby, E., 1981, Influence of in vivo hydrocortisone on some human blood lymphocyte populations, Scand. J. Immunol. 13:573–579.CrossRefPubMedGoogle Scholar
  52. Ortaldo, J. R., and Herberman, R. B., 1984, Heterogeneity of natural killer cells, Annu. Rev. Immunol 2:359–394.CrossRefPubMedGoogle Scholar
  53. Ortaldo, J. R., Sharrow, S. O., Timonen, T., and Herberman, R. B., 1981, Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies, J. Immunol 127:2401–2409.PubMedGoogle Scholar
  54. Oshimi, K., Oshimi, Y., Motoji, T., Kobayashi, S., and Mizoguchi, H., 1983, Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activated blood mononuclear cells, Blood 61:790–798.PubMedGoogle Scholar
  55. Pedersen, B. K., and Abom, B. 1986, Characterization of the in vitro effects of triethylphosphine gold (Auranofin) on human NK cell activity, Clin. Exp. Rheum. 4:249–253.Google Scholar
  56. Pedersen, B. K., and Beyer, J. M., 1986a, Characterization of the in vitro effects of glucocorticosteroids on NK cell activity, Allergy 41:220–224.CrossRefPubMedGoogle Scholar
  57. Pedersen, B. K., and Beyer, J. M., 1986b, A longitudinal study on the influence of azathioprine on natural killer (NK) cell activity, Allergy 41:286–289.CrossRefPubMedGoogle Scholar
  58. Pedersen, B. K., Beyer, J. M., Rasmussen, A., Klarlund, K., Pedersen, B. N., and Helin, P., 1984, Methylprednisolone pulse therapy induced fall in natural killer cell activity in rheumatoid arthritis, Acta Pathol Microbiol. Immunol Scand. (C) 92:319–323.Google Scholar
  59. Pedersen, B. K., Oxholm, P., Manthorpe, R., and Andersen, V, 1986, Interleukin 2 augmentation of the defective natural killer cell activity in patients with primary Sjøgren’s syndrome, Clin. Exp. Immunol 63:1–7.PubMedGoogle Scholar
  60. Perussia, B., Santoli, D., and Trinchieri, G., 1980, Interferon modulation of natural killer cell activity, Ann. NY Acad. Sci. 350: 55–62.CrossRefPubMedGoogle Scholar
  61. Perussia, B., Starr, S., Abraham, S., Fanning, V, and Trinchieri, G., 1983, Human natural killer cells analyzed by B73.1, a monoclonal antibody blocking Fc receptor functions. I. Characterization of the lymphocyte subset reactive with B73.1, J. Immunol 130:2133–2141.PubMedGoogle Scholar
  62. Perussia, B., Trinchieri, G., Jackson, A., Warner, N. L., Faust, J., Rumpold, H., Kraft, D., and Lanier, L. L., 1984, The Fc receptor for IgG on human natural killer cells: Phenotypic, functional and comparative studies with monoclonal antibodies, J. Immunol. 133:180–189.PubMedGoogle Scholar
  63. Pistoia, V., Cozzalino, F., and Ferrarini, M., 1985, More about NK cells and regulation of B cell activity, Immunol. Today 6: 287–288.CrossRefGoogle Scholar
  64. Pope, R. M., and Talal, N., 1985, Autoimmunity in rheumatoid arthritis, Concepts Immunpathol 1:219–250.Google Scholar
  65. Pross, H. F., and Baines, M. G., 1977, Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. VI. Abrief review, Cancer Immunol. Immunother. 3:75–85.CrossRefGoogle Scholar
  66. Riccardi, C., Vose, B. M., and Herberman, R. B., 1983, Modulation of IL-2-dependent growth of mouse NK cells by interferon and T lymphocytes, J. Immunol 130:228–232.PubMedGoogle Scholar
  67. Ritz, J., Schmidt, R. E., Michon, J., Hercend, T., and Schlossman, S. F., 1988, Characterization of functional surface structures on human natural killer cells, Adv. Immunol. 42:181–211.CrossRefPubMedGoogle Scholar
  68. Russell, A. S., and Miller, C., 1984, The activity of natural killer cells in patients with rheumatoid arthritis: I. The effect of drugs used in vivo, Clin. Exp. Rheumatol. 2:227–229.PubMedGoogle Scholar
  69. Santoli, D., Trinchieri, G., Zmijewski, C. M., and Koprowski, H., 1976, HLA-related control of spontaneous and antibody-dependent cell-mediated cytotoxic activity in humans, J. Immunol. 117:765–770.PubMedGoogle Scholar
  70. Scala, G., Allavena, P., Ortaldo, J. R., Herberman, R. B., and Oppenheim, J. J., 1985, Subsets of human large granular lymphocytes (LGL) exhibit accessory cell functions, J. Immunol. 134:3049–3055.PubMedGoogle Scholar
  71. Seeley, J. K., and Golub, S. H., 1978, Studies on cytotoxicity generated in human mixed lymphocyte cultures. II. Time course and target spectrum of several distinct concomitant cytotoxic activites, J. Immunol. 120:1415–1421.PubMedGoogle Scholar
  72. Shih, W. W. H., Ellison, G. W., Myers, L. W., Durkos-Smith, D., and Fahey, J. L., 1982, Locus of selective depression of human natural killer cells by azathioprine, Clin. Immunol. Immunopathol. 23:672–681.CrossRefPubMedGoogle Scholar
  73. Sibbitt, W. L., Jr., Likar, L., Spellman, C. W., and Bankhurst, A. D., 1983, Impaired natural killer cell activity in systemic lupus erythematosus: Relationship to interleukin-2 production, Arthritis Rheum. 26:1316–1320.CrossRefPubMedGoogle Scholar
  74. Sibbitt, W. L., Jr., Mathews, P. M., and Bankhurst, A. D., 1984, Impaired release of a soluble natural killer cytotoxic factor in systemic lupus erythematosus, Arthritis Rheum. 27:1095–1100.CrossRefPubMedGoogle Scholar
  75. Silver, R. M., Redelman, D., Zvaifler, N. J., and Naides, S., 1982, Studies of rheumatoid synovial fluid lymphocytes. I. Evidence for activated natural killer-(NK) like cells, J. Immunol. 128:1758–1763.PubMedGoogle Scholar
  76. Struyf, N. J., Snoeck, H. W., Bridts, C. H., De Clerck, L. S., and Stevens, W. J., 1990, Natural killer cell activity in Sjøgren’s syndrome and systemic lupus erythematosus: Stimulation with interferons and interleukin-2 and correlation with immune complexes, Ann. Rheum. Dis. 49:690–693.CrossRefPubMedGoogle Scholar
  77. Sørskaar, D., Førre, Ø., Albrechtsen, D., and Stavem, P., 1986, Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smoldering leukemia, Scand. J. Haematol. 37:154–161.CrossRefPubMedGoogle Scholar
  78. Takasugi, M., Mickey, M. R., and Terasaki, P. I., 1973, Reactivity of lymphocytes from normal persons on cultured tumor cells, Cancer Res. 33:2989–2902.Google Scholar
  79. Takasugi, M., Koide, Y., Akira, D., and Ramseyer, A., 1977, Specificities in natural cell-mediated cytotoxicity by the crosscompetition assay, Int. J. Cancer 19:291–297.CrossRefPubMedGoogle Scholar
  80. Targan, S., and Dorey, F., 1980, Interferon activation of “pre-spontaneous killer” (pre-SK) cells and alteration in kinetics of lysis of both “pre-SK” and active SK cells, J. Immunol 124:2157–2161.PubMedGoogle Scholar
  81. Taylor, H. G., Nixon, N., Sheeran, T. P., and Dawes, P. T., 1989, Rheumatoid arthritis and chronic lymphatic leukaemia, Clin. Exp. Rheumatol. 7:529–532.PubMedGoogle Scholar
  82. Thiele, D. L., and Lipsky, P. E., 1985, Modulation of human natural killer cell function by L-leucine methyl ester: Monocytedependent depletion from human peripheral blood mononuclear cells, J. Immunol. 134:786–793.PubMedGoogle Scholar
  83. Thoen, J., Waalen, K., and Førre, Ø., 1987, Natural killer (NK) cells at inflammatory sties in patients with rheumatoid arthritis and in IgM rheumatoid factor positive polyarticular juvenile rheumatoid arthritis, Clin. Rheumatol. 6:215–225.CrossRefPubMedGoogle Scholar
  84. Thoen, J., Helgetveit, K., Førre, Ø., Haile, Y., and Kåss, E., 1988, Effects of piroxicam and D-penicillamine on T lymphocyte subpopulations, natural killer cells and rheumatoid factor production in rheumatoid arthritis, Scand. J. Rheumatol 17:91–102.CrossRefPubMedGoogle Scholar
  85. Tilden, A. B., Abo, T., and Balch, C. M., 1983, Suppressor cell function of human granular lymphocytes identified by HNK-1 (Leu-7) monoclonal antibody, J. Immunol. 130:1171–1175.PubMedGoogle Scholar
  86. Timonen, T., Ranki, A., Saksela, E., and Hayry, P., 1979, Fractionation, morphological and functional characterization of effector cells responsible for human natural killer activity against cell-line targets, Cell. Immunol 48:121–132.CrossRefPubMedGoogle Scholar
  87. Timonen, T., Ortaldo, J. R., and Herberman, R. B., 1982a, Analysis by a single cell cytotoxicity of natural killer (NK) cell frequencies among human large granular lymphocytes and of the effects of IFN on their activity, J. Immunol. 128:2514–2521.PubMedGoogle Scholar
  88. Timonen, T., Ortaldo, J. R., Stadler, B. M., Onnard, G. D., Sharrow, S. O., and Herberman, R. B., 1982b, Cultures of purified human natural killer cells: Growth in the presence of interleukin 2, Cell. Immunol 72:178–185.CrossRefPubMedGoogle Scholar
  89. Ucker, D. S., 1987, Cytotoxic T lymphocytes and glucocorticoids activate an endogenous suicide process in target cells, Nature 327:62–64.CrossRefPubMedGoogle Scholar
  90. Ullberg, M., and Jondal, M., 1981, Recycling and target binding capacity of human natural killer cells, J. Exp. Med. 153:615–628.CrossRefPubMedGoogle Scholar
  91. Versluis, D. J., Metselaar, H. J., Bijma, A. M., Vaessen, L. M. B., Wenting, G. J., and Weimar, W., 1988, The effect of long-term cyclosporine therapy on natural killer cell activity, Transplant. Proc. (Suppl. 2) 20:179–185.PubMedGoogle Scholar
  92. Whiteside, T. L., and Herberman, R. B., 1989, The role of natural killer cells in human disease, Clin. Immunol. Immunpathol. 53: 1–23.CrossRefGoogle Scholar
  93. Yocum, D. E., Wilder, R. L., Dougherty, S., Kiippel, J. H., Pillemer, S., and Wahl, S., 1990, Immunologie parameters of response in patients with rheumatoid arthritis treated with cyclosporine A, Arthritis Rheum. 9:1310–1316.CrossRefGoogle Scholar
  94. Ytterberg, S. R., and Schnitzer, T. J., 1982, Serum interferon levels in patients with systemic lupus erythematosus, Arthritis Rheum. 25:401–406.CrossRefPubMedGoogle Scholar
  95. Zarling, J. M., Clouse, K. A., Biddison, W. E., and Kung, P. C., 1981, Phenotypes of human natural killer cell populations detected with monoclonal antibodies, J. Immunol. 127:2575–2580.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Dag Sørskaar
    • 1
  • Øystein Førre
    • 1
  1. 1.Oslo Sanitetsforening Rheumatism HospitalOslo 1Norway

Personalised recommendations